• Register
  • Login

Issues and Developments in Medicine and Medical Research Vol. 5

  • Home
  • About
  • Books
  • Testimonials
  • Editors
  • Charges
  • Submission
  • Contact
Advanced Search
  1. Home
  2. Books
  3. Issues and Developments in Medicine and Medical Research Vol. 5
  4. Chapters


L-DOPA/Capsazepine or L-DOPA/Rimonabant Co-Administration in an Experimental Parkinson Disease Model: Behavioral and Cellular Consequences

  • José Luis Ordoñez-Librado
  • Ana Luisa Gutierrez-Valdez
  • Jesus Espinosa-Villanueva
  • Enrique Montiel-Flores
  • Patricia Aley-Medina
  • Javier Sánchez-Betancourt
  • Claudia Dorado-Martínez
  • Leonardo Reynoso-Erazo
  • Rocío Tron-Alvarez
  • Vianey Rodríguez-Lara
  • Maria Rosa Avila-Costa

Issues and Developments in Medicine and Medical Research Vol. 5, 4 February 2022 , Page 35-60
https://doi.org/10.9734/bpi/idmmr/v5/2361C Published: 2022-02-04

  • View Article
  • Cite
  • Statistics
  • Share

Abstract

Objective: using the 6-OHDA lesion in rats, we evaluated the ability of rimonabant or capsazepine with the addition of L-DOPA in: (1) the severity of LIDs, the dyskinetic effects were assessed using measures of abnormal involuntary movements (AIMs); (2) the protection of dopaminergic cell loss; and (3) in the cytological differences between treatments through analyzing the number of dendritic spines of the striatal medium-sized spiny neurons and the neuropile preservation. Oral co-administration of each antagonist with L-Dopa significantly decreased LIDs. Our data demonstrate that co-administration of L-DOPA with CB1 or TVPR1 receptor antagonists result in a very efficient treatment to reduce AIMs by conserving some functional dopaminergic cells, which implies the well-preserved synaptology of less denervated striatum. Thus, consistent with other reports, cannabinoid antagonist-based therapy would not only be aimed at alleviating specific motor symptoms but also at delaying/arresting the degeneration of striatal and substantia nigra compacta cells.

Keywords:
  • L-DOPA
  • dyskinesia
  • Parkinson disease experimental model
  • endocannabinoid system antagonists
  • CB1
  • TRPV1
  • ultrastructure
  • cytology

How to Cite

Ordoñez-Librado, J. L. ., Gutierrez-Valdez, A. L. ., Espinosa-Villanueva, J. ., Montiel-Flores, E. ., Aley-Medina, P. ., Sánchez-Betancourt, J. . ., Dorado-Martínez, C. . ., Reynoso-Erazo, L. ., Tron-Alvarez, R. ., Rodríguez-Lara, V. ., & Avila-Costa, M. R. . (2022). L-DOPA/Capsazepine or L-DOPA/Rimonabant Co-Administration in an Experimental Parkinson Disease Model: Behavioral and Cellular Consequences. Issues and Developments in Medicine and Medical Research Vol. 5, 35–60. https://doi.org/10.9734/bpi/idmmr/v5/2361C
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX




  • Linkedin
  • Twitter
  • Facebook
  • WhatsApp
  • Telegram

© BP International